drugset / Trial / NCT04524858
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
Timeline
- Start
- 2020-10-23
- Primary completion
- 2021-02-25
- Completion
- 2021-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zunsemetinib | Small molecule | 50 mg | Oral |